icone plus
Contact Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TECENTRIQ (atezolizumab).
See also
Décision d'accès précoce
25/11/2022
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
EtDzK8e1N0AvLp8K
Listen
